Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.340 +0.030 (+2.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vivani Medical, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Vivani Medical, Inc. Announces Closing of Common Stock Offering
From Vivani Medical, Inc.
Via GlobeNewswire
News headline image
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces FDA Clears Investigational New Drug Application and Lifts Clinical Hold for NPM-119, a Miniature Long-Term Subdermal GLP-1 Drug Implant
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at TIDES Conference 2024
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
News headline image
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at BIO Investor Forum
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Present at the Boulder Peptide Symposium
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System
From Vivani Medical, Inc.
Via Business Wire
News headline image
Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
From Vivani Medical, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.